| Exclusion Criteria: | 1) Prior treatment with bortezomib
2) Hypersensitivity or allergic reactions to boron or mannitol, or compounds containing these components
3) >/= Grade 2 peripheral neuropathy (according to NCI CTCAE, Version 3.0)
4) Treatment with systemic cancer therapy (including clarithromycin) or radiotherapy within 30 days of randomization
5) Treatment with nitrosoureas within 42 days of first dose/randomization
6) Major surgery within 30 days of first dose/randomization or planning to have surgery (except for minor surgical procedures) during the study
7) Received any investigational drug/agent within 30 days or 5 half-lives (whichever is longer) of first dose/randomization
8) Received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant
9) Has clinically significant residual toxicities associated with prior autologous bone marrow or autologous peripheral blood stem cell transplant.
10) Administered platelet transfusion or neutrophil growth factor within 2 weeks prior to the collection of screening hematology laboratory sample
11) Transplanted solid organ with the exception of a corneal transplant (>/= 3 months prior to first dose/randomization)
12) Received any mAb within 60 days of first dose/randomization
13) Serious concurrent illness (medical or psychiatric), uncontrolled infection (including acute, diffuse infiltrative pulmonary disease), or any uncontrolled medical condition (eg, uncontrolled diabetes), including the presence of laboratory abnormalities, that places the subject at unacceptable risk by participating in the study or confounds the ability to interpret data from the study
14) Myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) Class II or higher heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemic, clinically significant conduction system abnormalities, baseline QTc interval > 450 milliseconds, history of hypokalemia, or any cardiac condition that is >/= Grade 3
15) Prior or concomitant malignancy (other than multiple myeloma) except adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or other cancer for which the subject has been disease-free for >/= 3 years
16) Any other concomitant disease-related treatment such as, immunotherapy, biotherapy, radiotherapy, chemotherapy, investigative therapy, or immunosuppressive therapy/corticoid steroids
17) Vaccinated with live, attenuated vaccines within 4 weeks of the first administration of CNTO 328/placebo
18) Known to be seropositive for HIV, or active hepatitis A, B or C infection
19) Pregnant or lactating women
20) Known allergies or clinically significant reactions to murine, chimeric, or human proteins |